Multidrug and toxin extrusion proteins as transporters of antimicrobial drugs

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 12, 2012, Pages 1565-1577

  Nies, Anne T ^a   Damme, Katja ^a   Schaeffeler, Elke ^a   Schwab, Matthias ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Drug drug interactions; Infectious diseases; SLC47; Solute carrier transporters; Transport function

Indexed keywords

ACICLOVIR; AMANTADINE; AMPRENAVIR; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ANTIVIRUS AGENT; CEFALEXIN; CEFRADINE; CHLORAMPHENICOL; CHLOROQUINE; CIMETIDINE; CIPROFLOXACIN; CLOTRIMAZOLE; GANCICLOVIR; KETOCONAZOLE; LEVOFLOXACIN; MULTIDRUG AND TOXIN EXTRUSION PROTEIN; ORGANIC CATION TRANSPORTER; PENTAMIDINE; PROGUANIL; PROTEIN MATE 2K; PROTEIN MATE1; PROTEIN MATE2; PYRIMETHAMINE; QUININE; RITONAVIR; TIPRANAVIR; TRIMETHOPRIM; UNCLASSIFIED DRUG;

BILE; DRUG DISPOSITION; DRUG EXCRETION; DRUG RESPONSE; DRUG STRUCTURE; DRUG TRANSPORT; GENETIC VARIABILITY; KIDNEY TUBULE CELL; LIVER CELL; MEMBRANE TRANSPORT; NONHUMAN; NUCLEOTIDE SEQUENCE; POPULATION GENETICS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; TISSUE DISTRIBUTION; URINE;

ANIMALS; ANTI-INFECTIVE AGENTS; BILE; DRUG INTERACTIONS; GENE EXPRESSION REGULATION; GENETIC VARIATION; HEPATOCYTES; HUMANS; KIDNEY TUBULES; MICE; MICE, KNOCKOUT; ORGANIC CATION TRANSPORT PROTEINS; RNA, MESSENGER; URINE;

EID: 84869413708     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.722996     Document Type: Review

References (73)

1. Fauci AS, Morens DM. The perpetual challenge of infectious diseases. N Engl J Med 2012;366:454-61
2. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9:215-36
3. Degorter MK, Xia CQ, Yang JJ, Kim RB. Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol 2012;52:249-73
4. Avilable from http://www.bioparadigms.org/slc/menu.asp
5. Otsuka M, Matsumoto T, Morimoto R, et al. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA 2005;102:17923-8
6. Omote H, Hiasa M, Matsumoto T, et al. The MATE proteins as fundamental transporters of metabolic and xenobiotic organic cations. Trends Pharmacol Sci 2006;27:587-93
7. Terada T, Masuda S, Asaka J, et al. Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm Res 2006;23:1696-701
8. Ohta KY, Inoue K, Hayashi Y, Yuasa H. Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H+ antiporter in the kidney. Drug Metab Dispos 2006;34:1868-74
9. Zhang X, Cherrington NJ, Wright SH. Molecular identification and functional characterization of rabbit MATE1 and MATE2-K. Am J Physiol Renal Physiol 2007;293:F360-70
10. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007;24:1227-51
11. Moriyama Y, Hiasa M, Matsumoto T, Omote H. Multidrug and toxic compound extrusion (MATE)-type proteins as anchor transporters for the excretion of metabolic waste products and xenobiotics. Xenobiotica 2008;38:1107-18
12. Terada T, Inui KI. Physiological and pharmacokinetic roles of H(+)/organic cation antiporters (MATE/SLC47A). Biochem Pharmacol 2008;75:1689-96
13. Yonezawa A, Inui K. Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol 2011;81:563-8
14. Masuda S, Terada T, Yonezawa A, et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 2006;17:2127-35
15. Tanihara Y, Masuda S, Sato T, et al. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol 2007;74:359-71
16. Asaka J, Terada T, Tsuda M, et al. Identification of essential histidine and cysteine residues of the H+/organic cation antiporter multidrug and toxin extrusion (MATE). Mol Pharmacol 2007;71:1487-93
17. Komatsu T, Hiasa M, Miyaji T, et al. Characterization of the human MATE2 proton-coupled polyspecific organic cation exporter. Int J Biochem Cell Biol 2011;43:913-18
18. Damme K, Nies AT, Schaeffeler E, Schwab M. Mammalian MATE (SLC47A) transport proteins: impact on efflux of endogenous substrates and xenobiotics. Drug Metab Rev 2011;43:499-523
19. Hiasa M, Matsumoto T, Komatsu T, et al. Functional characterization of testis-specific rodent multidrug and toxic compound extrusion 2, a class III MATE-type polyspecific H+/organic cation exporter. Am J Physiol Cell Physiol 2007;293:C1437-44
20. Yonezawa A, Inui KI. Importance of the Multidrug and Toxin Extrusion MATE/SLC47A Family to Pharmacokinetics, Pharmacodynamics/Toxicodynamics and Pharmacogenomics. Br J Pharmacol 2011;164:1817-25
21. Zhang X, Wright SH. MATE1 has an external COOH terminus, consistent with a 13-helix topology. Am J Physiol Renal Physiol 2009;297:F263-71
22. Zhang X, He X, Baker J, et al. Twelve transmembrane helices form the functional core of mammalian multidrug and toxin extruder 1 (MATE1). J Biol Chem 2012;287(33):27971-82
23. He X, Szewczyk P, Karyakin A, et al. Structure of a cation-bound multidrug and toxic compound extrusion transporter. Nature 2010;467:991-4
24. Choi JH, Yee SW, Ramirez AH, et al. A common 5'-UTR variant in MATE2-K is associated with poor response to metformin. Clin Pharmacol Ther 2011;90:674-84
25. K€onig J, Zolk O, Singer K, et al. Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations. Br J Pharmacol 2011;163:546-55
26. Hiasa M, Matsumoto T, Komatsu T, Moriyama Y. Wide variety of locations for rodent MATE1, a transporter protein that mediates the final excretion step for toxic organic cations. Am J Physiol Cell Physiol 2006;291:C678-86
27. Tsuda M, Terada T, Asaka J, et al. Oppositely directed H+ gradient functions as a driving force of rat H+/organic cation antiporter MATE1. Am J Physiol Renal Physiol 2007;292:F593-8
28. Kobara A, Hiasa M, Matsumoto T, et al. A novel variant of mouse MATE-1 H+/organic cation antiporter with a long hydrophobic tail. Arch Biochem Biophys 2008;469:195-9
29. Takano M, Inui K, Okano T, et al. Carrier-mediated transport systems of tetraethylammonium in rat renal brush-border and basolateral membrane vesicles. Biochim Biophys Acta 1984;773:113-24
30. Pritchard JB, Miller DS. Mechanisms mediating renal secretion of organic anions and cations. Physiol Rev 1993;73:765-96
31. Koepsell H. Organic cation transporters in intestine, kidney, liver, and brain. Annu Rev Physiol 1998;60:243-66
32. Yonezawa A, Masuda S, Yokoo S, et al. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and MATE family). J Pharmacol Exp Ther 2006;319:879-86
33. Ohta KY, Imamura Y, Okudaira N, et al. Functional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fluoroquinolones. J Pharmacol Exp Ther 2009;328:628-34
34. Kido Y, Matsson P, Giacomini KM. Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J Med Chem 2011;54:4548-58
35. Ito S, Kusuhara H, Kuroiwa Y, et al. Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J Pharmacol Exp Ther 2010;333:341-50
36. Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, et al. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2, and single nucleotide polymorphisms. Am J Physiol Renal Physiol 2010;298:F997-F1005
37. Kusuhara H, Ito S, Kumagai Y, et al. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 2011;89:837-44
38. Astorga B, Ekins S, Morales M, Wright SH. Molecular Determinants of Ligand Selectivity for the Human Multidrug And Toxin Extrusion Proteins, MATE1 and MATE-2K. J Pharmacol Exp Ther 2012;341:743-55
39. Watanabe S, Tsuda M, Terada T, et al. Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J Pharmacol Exp Ther 2010;334:651-6
40. Ohta KY, Inoue K, Yasujima T, et al. Functional characteristics of two human MATE transporters: kinetics of cimetidine transport and profiles of inhibition by various compounds. J Pharm Pharm Sci 2009;12:388-96
41. Nies AT, Koepsell H, Damme K, Schwab M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol 2011;1:105-67
42. Ito S, Kusuhara H, Yokochi M, et al. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther 2012;340:393-403
43. Sato T, Masuda S, Yonezawa A, et al. Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. Biochem Pharmacol 2008;76:894-903
44. Kajiwara M, Terada T, Asaka J, et al. Critical roles of Sp1 in gene expression of human and rat H+/organic cation antiporter MATE1. Am J Physiol Renal Physiol 2007;293:F1564-70
45. Ha Choi J, Wah Yee S, Kim MJ, et al. Identification and characterization of novel polymorphisms in the basal promoter of the human transporter. MATE1. Pharmacogenet Genomics 2009;19:770-80
46. Lu H, Gonzalez FJ, Klaassen C. Alterations in hepatic mRNA expression of phase II enzymes and xenobiotic transporters after targeted disruption of hepatocyte nuclear factor 4 alpha. Toxicol Sci 2010;118:380-90
47. Lickteig AJ, Cheng X, Augustine LM, et al. Tissue distribution, ontogeny and induction of the transporters Multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in mice. Life Sci 2008;83:59-64
48. Degorter MK, Kim RB. Use of Transgenic and Knockout Mouse Models to Assess Solute Carrier Transporter Function. Clin Pharmacol Ther 2011;89:612-16
49. Tsuda M, Terada T, Mizuno T, et al. Targeted disruption of the multidrug and toxin extrusion 1 (Mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol 2009;75:1280-6
50. Li Q, Peng X, Yang H, et al. Deficiency of multidrug and toxin extrusion 1 enhances renal accumulation of paraquat and deteriorates kidney injury in mice. Mol Pharm 2011;8:2476-83
51. Nakamura T, Yonezawa A, Hashimoto S, et al. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharmacol 2010;80:1762-7
52. Toyama K, Yonezawa A, Masuda S, et al. Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis. Br J Pharmacol 2012;166:1183-91
53. Lai Y, Sampson KE, Balogh LM, et al. Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1). J Pharmacol Exp Ther 2010;334:936-44
54. Takeda M, Khamdang S, Narikawa S, et al. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther 2002;300:918-24
55. Yokoo S, Yonezawa A, Masuda S, et al. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol 2007;74:477-87
56. Kerb R, Fux R, Morike K, et al. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infect Dis 2009;9:760-74
57. Opravil M, Keusch G, Luthy R. Pyrimethamine inhibits renal secretion of creatinine. Antimicrob Agents Chemother 1993;37:1056-60
58. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011;50:81-98
59. Imamura Y, Murayama N, Okudaira N, et al. Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion. Clin Pharmacol Ther 2011;89:81-8
60. van CJ, Bochner F, Keal J, Somogyi A. Selectivity of the cimetidine-induced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs. J Pharmacol Exp Ther 1986;236:481-7
61. Soyinka JO, Onyeji CO, Omoruyi SI, et al. Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. Br J Clin Pharmacol 2010;69:262-70
62. Chen Y, Teranishi K, Li S, et al. Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J 2009;9:127-36
63. Kajiwara M, Terada T, Ogasawara K, et al. Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity. J Hum Genet 2009;54:40-6
64. Toyama K, Yonezawa A, Tsuda M, et al. Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients. Pharmacogenet Genomics 2010;20:135-8
65. Hesselson SE, Matsson P, Shima JE, et al. Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation. PLoS One 2009;4:e6942
66. Kerb R, Schwab M. ADME pharmacogenetics and its impact on drug-drug interactions. In: Pang KS, Rodrigues AD, Peter RM, editors. Enzyme-and transporter-based drug-drug interactions: progress and future challenges. Springer; New York:2010. p. 51-74
67. Ichihara S, Kikuchi R, Kusuhara H, et al. DNA methylation profiles of organic anion transporting polypeptide 1B3 in cancer cell lines. Pharm Res 2010;27:510-16
68. Schaeffeler E, Hellerbrand C, Nies AT, et al. DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med 2011;3:82
69. Tsuda M, Terada T, Ueba M, et al. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther 2009;329:185-91
70. Müller F, K€onig J, Glaeser H, et al. Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother 2011;55:3091-8
71. Becker ML, Visser LE, van Schaik RH, et al. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 2009;58:745-9
72. Tzvetkov MV, Vormfelde SV, Balen D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009;86:299-306
73. Avilable from http://www.ncbi.nlm.nih.gov/pccompound